← feed

Is NCT03369002 results overdue?

Yes — results are overdue. Primary completion was 2018-05-15; the FDAAA-801 reporting deadline (2019-05-15) passed 2640 days ago and no results are posted on ClinicalTrials.gov.

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects

NCT IDNCT03369002 ↗
SponsorGilead Sciences (INDUSTRY)
Public issuerGILEAD SCIENCES, INC. — GILD (CIK 0000882095) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-05-15 (ACTUAL)
Reporting deadline2019-05-15 (completion + 365d)
Days overdue2640
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 aed47881898c4dd5… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03369002. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →